Latest:
Dr Richardson on Escalating Rates of Uterine Cancer Among Asian Americans
Michael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Dazhi Liu, PharmD, MS, BCOP
Latest:
Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLC
Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.
Jax DiEugenio
Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for
Latest:
Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer
A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.
Nathaniel Myall, MD
Latest:
Dr Myall on Immunotherapy Doublets and Chemoimmunotherapy in NSCLC
Nathaniel Myall, MD, clinical assistant professor, medicine - oncology, Stanford Medicine, discusses efficacy findings from 3 clinical trials investigating combination immunotherapy and chemoimmunotherapy treatment approaches in patients with non–small cell lung cancer.
Pau Montesinos, MD, PhD
Latest:
Dr Montesinos on Quizartinib Plus Chemotherapy in Newly Diagnosed FLT3-ITD Wild-Type AML
Pau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.
N. Arvind Dasari, MD, MS
Latest:
FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer
Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.